aphidicolin glycinate

DNA polymerase II inhibitor; RN given refers to(HCL(3R-(3alpha,4alpha,4aalpha,6abeta,8beta,9beta,11abeta,11bbeta)-isomer); RN for parent cpd without isomeric designation not avail 5/91

Also Known As:

Networked: 4 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Related Diseases

1.	Carcinoma (Carcinomatosis) 03/01/1991 - "Two recently established human ovarian carcinoma cell lines (JA-T and TR175) have been used to study the effects of aphidicolin glycinate (APG), a specific competitive inhibitor of DNA polymerase alpha (Ikegani et al. (1978) Nature, 275, 458-460), on the formation and removal of four platinum-DNA adducts. "
2.	Neoplasms (Cancer) 05/01/1999 - "Systemic administration of AphiG (60 mg/kg intraperitoneally, twice per day on 10 consecutive days) significantly suppressed tumor growth but was not able to induce any cures. " 01/01/1992 - "Potentiation of the activity of DDP by aphidicolin glycinate was moderate in mice bearing M5 tumor as well as in those bearing M5/DDP tumor. " 05/01/1999 - "In contrast, intratumoral AphiG injections (60 or 40 mg/kg/twice a day for 4 days) induced complete tumor regression. " 01/01/1992 - "Activity of aphidicolin glycinate alone or in combination with cisplatin in a murine ovarian tumor resistant to cisplatin." 05/01/1989 - "This method was applied to determine aphidicolin plasma levels in three cancer patients in Phase I clinical trials of aphidicolin-17-glycinate administered as a 1-h iv infusion. "
3.	Neuroblastoma 05/01/1999 - "These data strongly indicate that AphiG deserves further evaluation as a specific treatment for neuroblastoma." 05/01/1999 - "Aphidicolin glycinate inhibits human neuroblastoma cell growth in vivo."

Related Drugs and Biologics

1.	DNA Adducts
2.	Platinum
3.	DNA Polymerase I (Klenow Fragment)
4.	Aphidicolin
5.	Cisplatin (Platino)

Related Therapies and Procedures

1.	Injections